EMAIL THIS PAGE TO A FRIEND

Contraception

Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives.


PMID 18477490

Abstract

This retrospective analysis evaluated the association of age and weight with cycle control in women using either of two formulations of low-estrogen-dose oral contraceptives. Data for this secondary analysis were derived from a randomized multicenter trial assessing the efficacy and safety of norgestimate (NGM) 180/215/250 mcg/ethinyl estradiol (EE) 25 mcg (n=1506) and norethindrone acetate 1 mg/EE 20 mcg (n=1057). In this retrospective analysis, the incidence of breakthrough bleeding/spotting (BTB/S) was evaluated in women stratified by age (18-24, 25-34 and >34 years) and weight (155 lb). A lower percentage of women experienced BTB/S with NGM/EE during most cycles, regardless of age or weight, compared with norethindrone acetate/EE. At Cycle 6, the incidences of BTB/S for NGM/EE versus norethindrone acetate/EE were as follows: 18-24 years, 10.9% versus 29.7% (p<.0001); 25-34 years, 10.9% versus 18.6% (p<.001); >34 years, 8.1% versus 19.1% (p<.005); 155 lb, 10.0% versus 18.3% (p<.01). NGM/EE provided better cycle control as defined by BTB/S compared with norethindrone acetate/EE, regardless of subject age or weight for six cycles.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

94497
Norgestimate, analytical standard
C23H31NO3
SML0359
Norgestimate, ≥97% (HPLC)
C23H31NO3